By Admin at 7 Jan 2016

The FDA granted accelerated approval for Darzalex, which is a first-in-class immunotherapy treatment which works by helping your immune-system cells attack cancer cells. Darzalex is approved for patients who have received at least three prior treatments for multiple myeloma, meaning the disease has become resistant to the other treatments or has progressed within a short period of time after the last treatment.